A Phase 3 interventional study of CR845 in Uremic Pruritus, sponsored by Cara Therapeutics, Inc.. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-14.
Sponsored by Cara Therapeutics, Inc. (part of Tvardi Therapeutics, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing difelikefalin in Pruritus — 2 open to participants now, 2 under way, none of them phase 3. difelikefalin · Pruritus.
Among the 19 studies testing difelikefalin in Pruritus, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 9 in phase 3, and was the 3rd registered.
491 studies on the registry are indexed under Pruritus; 94 are open to participants now.
Browse Pruritus studies →2 of the 19 studies testing difelikefalin in Pruritus are open now, in 7 countries. Recruiting first, the newest first:
Vifor Fresenius Medical Care Renal Pharma · Sites in China, Greece, Israel and 4 more countries
Ages 12–18
Chittagong Medical College
Ages 18+
By country, each count listing its studies:
difelikefalin: first FDA approval 2021 (KORSUVA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 11
First in 2014; this study’s year is marked. 1 started in 2017.
This study's enrollment of 288 is above the median of 60 across 423 interventional studies indexed under Pruritus.
Median enrollment 226 across the 19 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
This study is registered under Cara Therapeutics, Inc., one of the names counted as Tvardi Therapeutics, Inc.. Under that name alone:
Cara Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 5 (33%) have results posted.
15 studies in Pruritus by Tvardi Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 14 finished, 6 (43%) have results posted.
Among the 15 studies in Pruritus by Tvardi Therapeutics, Inc., this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2017, is one of 7 in phase 3, and was the 3rd registered.
Tvardi Therapeutics, Inc.’s Pruritus studies by the year they started, since 2014.
1 of the studies testing difelikefalin in Pruritus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07526324Chittagong Medical CollegeDifelikefalin for Itching in Hemodialysis Patients With Chronic Kidney Disease | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing difelikefalin in Pruritus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Tvardi Therapeutics, Inc.’s 15 in Pruritus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.
This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks. This study will consist of a Screening Visit, a 52 week Treatment Period, and a Follow-up Visit. Informed consent will be obtained prior to performing any study-specific procedures. All patients will have a Screening Visit, which can be performed anytime within 14 days prior to the first dose of study drug, to confirm eligibility.
Clinical laboratory tests, electrocardiograms (ECGs), vital signs, adverse events, and concomitant medications will be monitored throughout the study. Blood samples for inflammatory biomarkers will be collected from all patients prior to dialysis on Day 1 and periodically until the End of Treatment or Early Termination Visit. Blood samples will also be collected periodically for clinical laboratory tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for inclusion into the study, a patient must meet the following criteria:
If female:
Has adequacy of dialysis, defined as meeting 1 of the following criteria during the 3 months prior to screening:
Exclusion Criteria:
A patient will be excluded from the study if any of the following criteria are met:
Has a concomitant disease or any medical condition that, in the opinion of the Investigator, could pose undue risk to the patient, impede completion of the study procedures, or would compromise the validity of the study measurements, including, but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CR845 0.5mcg/kg IV medication administered three times/week after dialysis
Drug: CR845
IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
Number of Participants With AEs
Assessed by physical examination, monitoring of adverse events, vital signs and laboratory assessments
Time frame: Up to 52 weeks
| Milestone | CR845 0.5mcg/kg |
|---|---|
| Started | 288 |
| Completed | 133 |
| Not completed | 155 |
Assessed by physical examination, monitoring of adverse events, vital signs and laboratory assessments
| Participants | CR845 0.5mcg/kg |
|---|---|
| Number of Participants With AEs | 240 |
Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CR845 0.5mcg/kg | 17/288 (5.9%) | 148/288 (51.4%) | 139/288 (48.3%) |
| Event | CR845 0.5mcg/kg |
|---|---|
| Fluid overloadMetabolism and nutrition disorders | 17/288 |
| HyperkalaemiaMetabolism and nutrition disorders | 15/288 |
| Acute myocardial infarctionCardiac disorders | 14/288 |
| PneumoniaInfections and infestations | 12/288 |
| SepsisInfections and infestations | 9/288 |
| HypotensionVascular disorders | 9/288 |
| Angina pectorisCardiac disorders | 8/288 |
| Cardiac arrestCardiac disorders | 8/288 |
| Cardiac failure congestiveCardiac disorders | 8/288 |
| Non-cardiac chest painGeneral disorders | 8/288 |
| Event | CR845 0.5mcg/kg |
|---|---|
| NauseaGastrointestinal disorders | 48/288 |
| DiarrhoeaGastrointestinal disorders | 44/288 |
| FallInjury, poisoning and procedural complications | 42/288 |
| VomitingGastrointestinal disorders | 38/288 |
| HypotensionVascular disorders | 30/288 |
| Non-cardiac chest painGeneral disorders | 22/288 |
| DizzinessNervous system disorders | 21/288 |
| Abdominal painGastrointestinal disorders | 18/288 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 16/288 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 15/288 |
| Age, Continuous(years) | CR845 0.5mcg/kg |
|---|---|
| Mean | 57.4 ± 12.61 |
| Sex: Female, Male(Participants) | CR845 0.5mcg/kg |
|---|---|
| Female | 115 |
| Male | 173 |
| Race (NIH/OMB)(Participants) | CR845 0.5mcg/kg |
|---|---|
| American Indian or Alaska Native | 12 |
| Asian | 9 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Black or African American | 148 |
| White | 114 |
| More than one race | 1 |
| Unknown or Not Reported | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Aug 2017 to primary completion in Feb 2020, 29 months.
Results were first posted in Oct 2021, 1 year 8 months after primary completion. A results delay was requested in Feb 2021.
Of 42 industry-sponsored phase 3 interventional studies under Pruritus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's 29 months is above that.
Counting every sponsor, half of 48 studies reached it within 19 months; a quarter within 12 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Difelikefalin